On this basis, Couëtoux et al. successfully that lung adenocarcinoma patients with HIP1-ALK (H28:A20) responded well to crizotinib, and the PFS could reach 26.9 months [94]. The gene discussed is ALK; the disease is lung adenocarcinoma.